Furthermore, pre-treatment with GLP-1 in patients with coronary artery disease undergoing elective percutaneous coronary intervention, protected the heart against ischemic LV dysfunction, independent of cardiac substrate use [52]. This evidence concerns the gene GCG and coronary artery disorder.